Lokelma AstraZeneca AB · Authorised · authorised 22 Mar 2018 · ATC V03AE10
Therapeutic indication (EMA)
Lokelma is indicated for the treatment of hyperkalaemia in adult patients.
Active substance
Sodium zirconium cyclosilicate
- SFDA 2
- US FDA 2
- EMA 1
- Health Canada 2
- US price lines 2
- NHS prices 3
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Lokelma | 5 g | Powder for oral suspension · Oral use | 30 Sachet | SAR 1057.40 | NCE · Prescription | AstraZeneca AB | Valid |
| Lokelma | 10 g | Powder for oral suspension · Oral use | 30 Sachet | SAR 1500.85 | NCE · Prescription | AstraZeneca AB | Valid |
Indications — CHI Daman Drug Formulary
HYPERKALEMIA
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| LOKELMA | 5GM/PACKET; 10GM/PACKET | for suspension · oral | ASTRAZENECA | Prescription | 18 May 2018 |
| SODIUM ZIRCONIUM CYCLOSILICATE | 5GM/PACKET; 10GM/PACKET | for suspension · oral | LUPIN | Prescription | 7 Aug 2026 |
EMA European Union — centrally authorised medicines
Canada Canada — marketed products (Health Canada)
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | LOKELMA 10 GRAM POWDER PACKET | $28.33002 | per EA | 23 Sep 2026 |
| US NADAC | LOKELMA 5 GRAM POWDER PACKET | $28.36158 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Sodium zirconium cyclosilicate 10g oral powder sachets | £31.20 | 3 sachet | 1 Oct 2026 |
| NHS Drug Tariff | Sodium zirconium cyclosilicate 10g oral powder sachets | £312.00 | 30 sachet | 1 Oct 2026 |
| NHS Drug Tariff | Sodium zirconium cyclosilicate 5g oral powder sachets | £156.00 | 30 sachet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 8 Feb 2024 LOKELMA — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.